Cerevel Therapeutics Initiates Phase 3 Program of Tavapadon for ...

In the news Cerevel Therapeutics Initiates Phase 3 Program of Tavapadon for the Treatment of Parkinson's Disease Studies to Enroll ...

Cerevel Therapeutics Announces Positive Topline Results for ...

Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-3 ... program is evaluating the efficacy, safety and tolerability of tavapadon ...

Press Release Details - Investor Relations | Cerevel Therapeutics

Initiation of the registration-directed Phase 3 program for tavapadon began in January 2020. In response to the COVID-19 pandemic, Cerevel ...

Parkinson Agent Tavapadon Meets Primary and Secondary End ...

Cerevel Therapeutics announces positive topline results for tavapadon in phase 3 adjunctive trial for people living with Parkinson disease.

AbbVie News Center - News

Cerevel Therapeutics Initiates Phase 3 Program of Tavapadon for the Treatment of Parkinson's Disease. December 08, 2019. Cerevel Therapeutics Announces Phase ...

AbbVie's $8.7B Cerevel Buy Starts to Pay off With Phase III ...

Results from TEMPO-1, which showed that tavapadon significantly improved motor symptoms in patients with Parkinson's disease, ...

Cerevel Therapeutics Initiates Phase 3 Program Testing Tavapadon...

Cerevel Therapeutics is launching a series of Phase 3 trials to evaluate tavapadon, designed to improve motor function in people with ...

$125M Non-Dilutive Financing for Tavapadon

Cerevel Therapeutics Reveals Encouraging Initial Outcomes from ...

Cerevel Therapeutics Reveals Encouraging Initial Outcomes from Phase 3 Supplementary Study of Tavapadon in Parkinson's Disease Patients. 23 April 2024. 3 ...

Cerevel Therapeutics Announces First Patients Dosed in all Phase 3 ...

Initiation of the registration-directed Phase 3 program for tavapadon began in January 2020. In response to the COVID-19 pandemic, Cerevel Therapeutics ...

Cerevel Therapeutics Announces Positive Topline Results for

Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-3 ... program is evaluating the efficacy, safety and tolerability of tavapadon ...

Cerevel Therapeutics Announces Strategic $125 Million Non ...

Risk-sharing arrangement with NovaQuest and Bain Capital will fund the full tavapadon Phase 3 development program for Parkinson's disease ...

Cerevel Therapeutics Announces Strategic $125 Million

Risk-sharing arrangement with NovaQuest and Bain Capital will fund the full tavapadon Phase 3 development program for Parkinson's disease ...

Cerevel Therapeutics Initiates Phase 3 Program of Tavapadon for ...

Cerevel Therapeutics Initiates Phase 3 Program of Tavapadon for the Treatment of Parkinson's Disease. Published on: Wednesday, 15 January ...

Cerevel Therapeutics Announces Positive Results from a Phase 2 ...

Over the course of 2020, we plan to initiate a robust Phase 3 development program to fully characterize the utility of tavapadon in patients ...

Cerevel Therapeutics Announces First Patients Dosed in all Phase 3 ...

Initiation of the registration-directed Phase 3 program for tavapadon began in January 2020. In response to the COVID-19 pandemic, Cerevel ...

Tavapadon - Cerevel Therapeutics

Tavapadon We are developing our most advanced therapeutic candidate, tavapadon, for the treatment of both early- and late-stage Parkinson's disease.

Cerevel notches Phase 3 Parkinson's win ahead of AbbVie ...

... Cerevel reported a Phase 3 win for one of its programs in Parkinson's disease. Patients taking the biotech's once-daily drug, called tavapadon ...

Cerevel's Tavapadon Meets Primary End Point in Phase 3 TEMPO-3 ...

According to a recent announcement, Cerevel Therapeutics' investigational agent tavapadon ... TEMPO-3 is part of a larger phase 3 program that ...

Positive Phase 3 Trial Results for Cerevel's Tavapadon

On April 18th, Cerevel reported positive results from its Phase 3 TEMPO-3 trial for tavapadon, a D1/D5 receptor partial agonist aimed at ...